{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:40:03Z","timestamp":1792086003323,"version":"4.4.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,6]]},"DOI":"10.1093\/jnci\/djr060","type":"journal-article","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T01:45:23Z","timestamp":1300758323000},"page":"553-561","source":"Crossref","is-referenced-by-count":357,"title":["Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib"],"prefix":"10.1093","volume":"103","author":[{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Antolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Della Casa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"D\u2019Emilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"le Coutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Hurtado-Monroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Piccin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muheez A.","family":"Durosinmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onno","family":"Leeksma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Maria","family":"Pogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjung","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josy","family":"Reiffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Valsecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,3,21]]},"reference":[{"issue":"14","key":"key\n\t\t\t\t20170521000005_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med."},{"issue":"9","key":"key\n\t\t\t\t20170521000005_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med."},{"issue":"11","key":"key\n\t\t\t\t20170521000005_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med."},{"issue":"23","key":"key\n\t\t\t\t20170521000005_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med."},{"issue":"3","key":"key\n\t\t\t\t20170521000005_bib5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood."},{"issue":"6","key":"key\n\t\t\t\t20170521000005_bib6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia."},{"issue":"2","key":"key\n\t\t\t\t20170521000005_bib7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol."},{"issue":"6022","key":"key\n\t\t\t\t20170521000005_bib8","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph1 translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature."},{"issue":"6","key":"key\n\t\t\t\t20170521000005_bib9","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2401811","article-title":"Detection and quantification of residual disease in chronic myelogenous leukemia","volume":"14","author":"Hochhaus","year":"2000","journal-title":"Leukemia."},{"issue":"35","key":"key\n\t\t\t\t20170521000005_bib10","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t20170521000005_bib11"},{"key":"key\n\t\t\t\t20170521000005_bib12"},{"issue":"1","key":"key\n\t\t\t\t20170521000005_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/oxfordjournals.aje.a009371","article-title":"Maximum (Max) and Mid-P confidence intervals and p values for the standardized mortality and incidence ratios","volume":"147","author":"Kulkarni","year":"1998","journal-title":"Am J Epidemiol."},{"key":"key\n\t\t\t\t20170521000005_bib14","article-title":"Analyzing","author":"Marubini","year":"1995"},{"key":"key\n\t\t\t\t20170521000005_bib15","volume-title":"SAS OnlineDoc 9.1.3","author":"SAS","year":"2002\u20132005"},{"key":"key\n\t\t\t\t20170521000005_bib16"},{"issue":"9373","key":"key\n\t\t\t\t20170521000005_bib17","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/S0140-6736(03)13554-4","article-title":"Gynaecomastia in men with chronic myeloid leukaemia after imatinib","volume":"361","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet."},{"issue":"22","key":"key\n\t\t\t\t20170521000005_bib18","first-page":"1127","article-title":"Comparison of steady-state imatinib (IM) trough levels, clinical response, and safety between Caucasian and Asian patients with chronic lyeloid leukemia in chronic phase (CML-CP) treated with 400mg and 800mg daily doses of IM in the tyrosine kinase inhibitor optimization and selectivity (TOPS) study","volume":"114","author":"Kim","year":"2009","journal-title":"ASH Annual Meeting Abstracts."},{"issue":"6","key":"key\n\t\t\t\t20170521000005_bib19","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol."},{"issue":"9","key":"key\n\t\t\t\t20170521000005_bib20","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2002.06.077","article-title":"Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation","volume":"20","author":"Kiss","year":"2002","journal-title":"J Clin Oncol."},{"issue":"21","key":"key\n\t\t\t\t20170521000005_bib21","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. Chronic Myeloid Leukemia Trialists\u2019 Collaborative Group","volume":"89","author":"Group CMLTC","year":"1997","journal-title":"J Natl Cancer Inst."},{"issue":"9","key":"key\n\t\t\t\t20170521000005_bib22","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1093\/aje\/kwq262","article-title":"Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study","volume":"172","author":"Rebora","year":"2010","journal-title":"Am J Epidemiol."},{"issue":"20","key":"key\n\t\t\t\t20170521000005_bib23","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol."},{"issue":"8","key":"key\n\t\t\t\t20170521000005_bib24","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer."},{"issue":"26","key":"key\n\t\t\t\t20170521000005_bib25","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1056\/NEJMe058314","article-title":"Expression of concern: Bombardier C, et al. \u201cComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,\u201d N Engl J Med 2000;343:1520\u20138","volume":"353","author":"Curfman","year":"2005","journal-title":"N Engl J Med."},{"issue":"1","key":"key\n\t\t\t\t20170521000005_bib26","first-page":"8","article-title":"Drug","volume":"56","author":"Angell","year":"2009","journal-title":"New York Rev Books."},{"issue":"22","key":"key\n\t\t\t\t20170521000005_bib27","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood."}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/103\/7\/553\/17311698\/djr060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T07:08:27Z","timestamp":1503558507000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article-lookup\/doi\/10.1093\/jnci\/djr060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,21]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,3,21]]},"published-print":{"date-parts":[[2011,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djr060","relation":{},"ISSN":["1460-2105","0027-8874"],"issn-type":[{"value":"1460-2105","type":"electronic"},{"value":"0027-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,21]]}}}